@article{16231,
  author = {Gao P. and Dans A. and Unger T. and Schumacher H. and Sleight P. and Diener H. and Probstfield J. and Diaz R. and Holman R. and Fagard R. and Dagenais G. and ARB Trialists Collaboration and McMurray J. and Pfeffer M. and Lindholm L. and Yusuf S. and Weber M. and Zanchetti A. and Connolly S. and Swedberg K. and Granger C. and Sjoelie A. and Massie B. and Carson P. and Lewis J. and Wachtell K. and Dahlöf B. and Devereux R. and Kjeldsen S. and Julius S. and Ibsen H. and Olsen M. and Okin P. and Califf R. and Haffner S. and Teo K. and Levine M. and Sacco R. and Cohn J. and Solomon S. and Velazquez E. and Anderson Craig},
  title = {Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals},
  abstract = {<p>
Background: Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs) reduce cardiovascular disease (CVD) events, but a recent meta-analysis of selected studies suggested that ARBs may increase cancer risks. Objective: Candesartan, irbesartan, telmisartan, valsartan, and losartan were assessed for incident cancers in 15 large parallel long-term multicenter double-blind clinical trials of these agents involving 138 769 participants. Patients and methods: Individuals at high CVD risk were randomized to telmisartan (three trials, n = 51 878), irbesartan (three trials, n = 14 859), valsartan (four trials, n = 44 264), candesartan (four trials, n = 18 566), and losartan (one trial, n = 9193) and followed for 23–60 months. Incident cancer cases were compared in patients randomized to ARBs versus controls. In five trials (n = 42 403), the ARBs were compared to ACEi and in 11 trials (n = 63 313) to controls without ACEi. In addition, in seven trials (n = 47 020), the effect of ARBs with ACEi was compared to ACEi alone and in two trials ARBs with ACEi versus ARB alone (n = 25 712). Results: Overall, there was no excess of cancer incidence with ARB therapy compared to controls in the 15 trials [4549 (6.16%) cases of 73 808 allocated to ARB versus 3856 (6.31%) of 61 106 assigned to non-ARB controls; odds ratio (OR) 1.00, 95% confidence interval (CI) 0.95–1.04] overall or when individual ARBs were examined. ORs comparing combination therapy with ARB along with ACEi versus ACEi was 1.01 (95% CI 0.94–1.10), combination versus ARB alone 1.02 (95% CI 0.91–1.13), ARB alone versus ACEi alone 1.06 (95% CI 0.97–1.16) and ARB versus placebo/control without ACEi 0.97 (95% CI 0.91–1.04). There was no excess of lung, prostate or breast cancer, or overall cancer deaths associated with ARB treatment. Conclusion: There was no significant increase in the overall or site-specific cancer risk from ARBs compared to controls.
</p>
},
  year = {2011},
  journal = {Journal of Hypertension},
  volume = {29},
  number = {4},
  pages = {623-635 10.1097/HJH.0b013e328344a7de},
  isbn = {0263-6352},
  language = {eng},
}